期刊文献+

基于“肠-脑”通路探讨帕金森病的发病机制的研究现状 被引量:11

Current situation of exploring the pathogenesis of Parkinson’s disease based on the"gut-brain"pathway
原文传递
导出
摘要 帕金森病因其神经精神功能及肢体运动功能障碍影响患者生存质量,其发病机制不明,当前仍然以药物治疗为重点。以左旋多巴为主的药物治疗可以通过补充黑质纹状体内的多巴胺来缓解以静止性震颤为主的临床症状,但其药物不良反应较大,同时药物时效性难以长久维持。探明导致帕金森病的发病机制,寻求新的干预靶点是未来防止病情发展的关键,而肠道菌群失衡导致的大脑神经功能障碍即"肠-脑"通路受阻可能是其重要机制之一。 The causes of Parkinson’s disease include neuropsychiatric function and limb motor dysfunction,which mainly affect the quality of life of patients.In addition,the pathogenesis is unknown.Therefore,drug therapy is still the focus at present to prevent the progressive development of the disease.Now is given priority to with levodopa drug treatments can complement the substantia nigra striatal dopamine in the body to relieve the clinical symptoms predominantly static tremor,but its side effect is bigger,drug timeliness is difficult to maintain for a long time at the same time,therefore,proven lead to the pathogenesis of Parkinson’s disease,seek new intervention targets is the key to the future to prevent illness development.The brain neurological dysfunction caused by the imbalance of intestinal flora,namely the obstruction of the"entero-brain"pathway,may be one of the important mechanisms.
作者 何彦虎 金华 刘志军 刘敏科 苏莉莉 司美龙 HE Yan-hu;JIN Hua;LIU Zhi-jun;LIU Min-ke;SU Li-li;SI Mei-long(Clinical College of Traditional Chinese Medicine(TCM),Gansu University of TCM,Lanzhou 730000,Gansu Province,China;Key Laboratory of Dunhuang Medicine,Ministry of Education,Gansu University of TCM,Lanzhou 730000,Gansu Province,China;Affiliated Hospital of Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2021年第23期3290-3294,共5页 The Chinese Journal of Clinical Pharmacology
基金 国家自然科学基金资助项目(81560716 81860832) 甘肃省高等学校协同创新团队基金资助项目(2017C-14) 甘肃省中医药科研课题基金资助项目(GZK-2019-24)。
关键词 帕金森病 肠道菌群 左旋多巴 多巴胺 肠-脑通路 发病机制 Parkinson’s disease intestinal flora levodopa dopamine gut-brain pathway pathological mechanism
  • 相关文献

参考文献21

二级参考文献125

  • 1孙斌,罗毅.帕金森病的现代药物治疗[J].医药导报,2005,24(2):85-90. 被引量:8
  • 2黄娟.帕金森综合症的病因分析及其治疗分析研究[J].医药前沿,2015(20):83.
  • 3AIDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease[J]. Neurotherapeutics, 2014, 11:6-23.
  • 4Mhyre TR, Boyd JT, Hamill RW, et al. Parkinson's disease[J]. Subcell Biochem, 2012, 65:389-455.
  • 5McGeer PL, Itaqaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains[J]. Neurology, 1988, 38:1285-1291.
  • 6Akiyama H, McGeer PL. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions[J]. Brain Res, 1989, 489:247-253.
  • 7Depino AM, Earl C, Kaczmarczyk E, et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease[J]. Eur J Neurosci, 2003, 18:2731-2742.
  • 8McGeer PL, Schwab C, Parent A, et al. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration[J]. Ann Neurol, 2003, 54:599-604.
  • 9Ransohoff RM, Perry VH. Microglial physiology:unique stimuli, specialized responses[J]. Annu Rev Immunol, 2009, 27:119-145.
  • 10Takeuchi H, Jin SJ, Wang JY, et al. Tumor necrosis factor-α induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner[J]. J Biol Chem, 2006, 281:21362-21368.

共引文献286

同被引文献185

引证文献11

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部